Despite some limitations, this meta-analysis suggested that the GSTM1 null genotype was associated with enhanced risk of prostate cancer carcinogenesis, but non-significant association was observed for GSTT1 deletion with prostate cancer risk. This evidence concerns the gene GSTM1 and prostate carcinoma.